CD274 and neoplasm: Based on these findings, PD-L1 expression on tumor or immune cells has emerged as a predictive biomarker for sensitivity to ICIs, and immunohistochemistry (IHC) assays to evaluate PD-L1 expression have been approved by the US FDA as a companion diagnostic for immunotherapy with ICIs in specific tumor types [10,11].